People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Other Health Care, Biotechnology, Healthtech, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Conventus Orthopaedics Inc | — | Other Health Care | Series C | $144.2M | $921.2M | 2009 |
| Shoulder Innovations, Inc. | — | Other Health Care | Series B | $84.7M | $106.9M | 2020 |
| SentreHEART Inc | — | Biotechnology | Series B | $51.0M | $992.2M | 2012 |
| Miromatrix Medical Inc. | — | Biotechnology | Series B | $44.8M | $623.9M | 2017 |
| CHF Solutions, Inc. | — | Biotechnology | Series A | $33.0M | $17.1M | 2012 |
| Pathway Medical Technologies Inc | — | Biotechnology | Series A | $9.9M | $359.1M | 2010 |
| Aortica Corp | — | Biotechnology | Series A | $8.0M | $37.1M | 2017 |
| NexGen Medical Systems Inc | — | Healthtech | Seed | $3.5M | $13.4M | 2018 |
| ActivOrtho, Inc. | — | Other Technology | Seed | $2.6M | $7.0M | 2018 |
| NeuroOne, Inc. | — | Biotechnology | Seed | $1.5M | $67.7M | 2016 |
Paul Buckman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Paul Buckman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Casey Tansey | 2 | 14 |
| Steven Hochberg | 2 | 9 |
| J. Daniel Cole | 2 | 7 |
| Robert A Kukuljan | 2 | 6 |
| David A. Rosa | 2 | 5 |
| David Blue | 2 | 5 |
| Michael Brenzel | 2 | 3 |
| Paul Hindrichs | 2 | 3 |
| Paul A Buckman | 2 | 3 |
| Michael P Brenzel | 2 | 2 |
| Richard Ferrari | 1 | 15 |
| Robert Cohen | 1 | 11 |
| Russell Hirsch | 1 | 10 |
| Kevin Sidow | 1 | 7 |
| John Deedrick | 1 | 7 |
| Andrew ElBardissi | 1 | 7 |
| Chen Yu | 1 | 7 |
| Robert Ball | 1 | 7 |
| Rudy Mazzocchi | 1 | 6 |
| Geoff Pardo | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.